News & Events

Redbiotec has been selected to present its CMV Vaccine program at the CMV 2012 Meeting in San Francisco starting October 31. Pharma companies including Novartis, Sanofi Pasteur, MedImmune, Boehringer Ingelheim with leading CMV activities will also join the meeting.

Redbiotec is pleased to announce that the project started with Merck Sharp & Dohme Corp. (NJ, USA) in October 2011, in which Redbiotec applies its proprietary technology platform rePAX® to an undisclosed discovery area, has reached a first milestone successfully and was therefore extended. We look forward to the ongoing collaboration with Merck!

Redbiotec today announced that it has closed an agreement with a listed, leading biopharmaceutical company in the field of prime-boost for cancer therapeutics to validate the approach. Christian Schaub, CEO of Redbiotec, states: “This is a major step for Redbiotec and a further proof of Redbiotec’s leadership in the development and production of complex VLPs.” Redbiotec develops VLPs for three main fields: 1) VLP vaccines, 2) VLPs for prime-boost / enhancement of cancer therapeutics and 3) VLPs, expressing GPCRs and ion channels, as targets for antibody screening.

Redbiotec today announced that it has closed a new collaboration agreement with an undisclosed company in the field of antibody generation. The goal of this collaboration is the development of new therapeutic antibodies using Redbiotec’s VLPs as targets. Under the agreement, the parties will share profit generated by the therapeutic antibodies.

The challenge experiment using Redbiotec’s tetravalent influenza VLPs was successfully finalized. Results obtained clearly show that influenza VLPs are capable of stimulating the humoral and cellular immune responses which neutralize and inhibit replication of a challenge virus. When immunized mice were challenged with a lethal dose of the parental virus, 100% of mice were protected.